10x Genomics, Inc.
For the period ended Jun 30, 2026. Filed Aug 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 7, 2026
TXG$65.05+9.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Products and services revenue | $149,094 | $145,157 | $298,990 | $282,980 |
| License and royalty revenue | 1,942 | 27,751 | 2,889 | 44,811 |
| Revenue | 151,036 | 172,908 | 301,879 | 327,791 |
| Cost of products and services revenue | 38,539 | 47,824 | 83,204 | 97,262 |
| Gross profit | 112,497 | 125,084 | 218,675 | 230,529 |
| Operating expenses: | ||||
| Research and development | 56,791 | 61,224 | 113,638 | 125,469 |
| Selling, general and administrative | 78,661 | 74,434 | 145,038 | 164,162 |
| Gain on settlement | (3,400) | (40,700) | (3,400) | (49,900) |
| Total operating expenses | 132,052 | 94,958 | 255,276 | 239,731 |
| Income (loss) from operations | (19,555) | 30,126 | (36,601) | (9,202) |
| Other income (expense): | ||||
| Interest income | 4,797 | 4,271 | 9,811 | 7,957 |
| Interest expense | — | (3) | — | (3) |
| Other income (expense), net | (3,887) | 2,603 | (4,702) | 4,739 |
| Total other income | 910 | 6,871 | 5,109 | 12,693 |
| Income (loss) before provision for income taxes | (18,645) | 36,997 | (31,492) | 3,491 |
| Provision for (benefit from) income taxes | (714) | 2,459 | (91) | 3,311 |
| Net income (loss) | $(17,931) | $34,538 | $(31,401) | $180 |
| Net income (loss) per share, basic | $(0.14) | $0.28 | $(0.24) | $0.00 |
| Net income (loss) per share, diluted | $(0.14) | $0.28 | $(0.24) | $0.00 |
| Weighted-average shares used to compute net income (loss) per share, basic | 129,984,169 | 123,755,409 | 129,050,312 | 123,183,924 |
| Weighted-average shares used to compute net income (loss) per share, diluted | 129,984,169 | 124,509,720 | 129,050,312 | 124,258,150 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.